Kornimate/medical-research-clean huggingface dataset:
a study of diffusing alpha radiation therapy for target treatments of malignant tumors

Conditions: Malignant Tumor

Summary: this study is a compassionate clinical study for the treatment of malignant tumors. the primary endpoint of the study is to assess the frequency, severity and causality of acute adverse events related to the dart treatment. adverse events will be assessed and graded according to common terminology and criteria for adverse events (ctcae) version 5.0. the secondary endpoint is to assess the tumor response to dart treatment assessed using the response evaluation criteria in solid tumors (recist) (version 1.1) 3 months after dart seed insertion.

this is an open label, one arm, prospective study for compassionate use for the treatment of malignant tumors. the study objectives are to collect data on the safety and efficacy of dart among patients who do not fit the entry of existing investigational trials. the primary endpoint of the study is to assess the frequency, severity and causality of acute adverse events related to the dart treatment. adverse events will be assessed and graded according to common terminology and criteria for adverse events (ctcae) version 5.0. the secondary endpoint is to assess the tumor response to dart treatment assessed using the response evaluation criteria in solid tumors (recist) (version 1.1) 3 months after dart seed insertion.

Eligibility criteria:
inclusion criteria: * subjects with any malignancy * subjects with a tumor size ≤ 7 centimeters in the longest diameter * subjects over 18 years old * subjects' life expectancy is more than 6 months * women of childbearing potential (wocbp) will have evidence of negative pregnancy test and are required to use an acceptable contraceptive method to prevent pregnancy for 3 months after treatment. * subjects/surrogate decision maker are willing to sign an informed consent form exclusion criteria: * known hypersensitivity to any of the components of the treatment. * clinically significant cardiovascular disease, e.g. cardiac failure of new york heart association classes iii-iv, uncontrolled coronary artery disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or history of myocardial infarction in the last 12 months. * any medical or psychiatric illness which in the opinion of the investigator would compromise the patient's ability to tolerate this treatment or interfere with the study endpoints. * volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of dart. * patients must agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after discontinuing therapy. * high probability of protocol non-compliance (in opinion of investigator). * subjects/surrogate decision maker not willing to sign an informed consent. * women who are pregnant or breastfeeding.

Keywords: tumor malignant tumor cancer brachytherapy alpha emitting radiation compassionate treatment
effectiveness of dupilumab in food allergic patients with moderate to severe atopic dermatitis

Conditions: Food Allergy

Summary: this study evaluates the effectiveness of dupilumab in food allergic patients with moderate to severe atopic dermatitis (ad). included patients participated in the bioday registry.

the positive results of the dupilumab studies in ad, asthma and nasal polyposis with chronic sinusitis validate the fundamental role for il-4 and il-13 in the pathogenesis of these diseases, and add to the possibility that these cytokines are also critically involved in other related allergic/atopic (type 2 immune) diseases that are often co-morbidly associated with ad, such as food allergy.

Eligibility criteria:
inclusion criteria: 1. ad patients with moderate to severe ad who are indicated for treatment with dupilumab 2. peanut, hazelnut, walnut, cow's milk, hen's egg and/or soybean allergy allergic subjects, with a well-documented medical history of reactions after ingestion.peanut, hazelnut, walnut, cow's milk, hen's egg and/or soybean allergy specific immunoglobulin e (ige) level (phadia cap-system) higher than 0.35 ku/l or a skin prick test of at least 3 mm 3. positive double-blind placebo-controlled food challenge (dbpcfc) with an eliciting dose before the last dose 4. signed bioday informed consent from subjects exclusion criteria: 1. subjects reacting objectively to the placebo at screening. 2. subjects in whom dbcpfc is contra-indicated or in whom dbpcfc is not reliable

Keywords: dupilumab food allergy atopic dermatitis bioday registry
postoperative supplemental oxygen in liver transplantation

Conditions: Infection

Summary: the aim of this prospective randomized controlled trial is to evaluate the impact of high concentration supplemental postoperative oxygen therapy on short-term and long-term results of liver transplantation, particularly with respect to infections and biliary complications.

the aim of this prospective randomized controlled trial is to evaluate the impact of high concentration supplemental postoperative oxygen therapy on short-term and long-term results of liver transplantation, particularly with respect to infections and biliary complications. a total of 296 patients immediately after liver transplantation will be randomly assigned to receive either 80% (high concentration) or 28% (controls) fraction of inspired oxygen for 6 hours after surgery with a 1:1 allocation ratio. patients will be blinded to the type of received intervention. randomization will be stratified by the child-turcotte-pugh classification. both groups will be compared to short- and long-term outcome measures.

Eligibility criteria:
inclusion criteria: * active liver transplant waitlist status exclusion criteria: * active infection at the time of transplantation * malignancy * cardiac arrest during transplantation * chronic obstructive pulmonary disease * acute myocardial infarction

Keywords: liver transplantation postoperative infection biliary complications patient survival graft survival supplemental oxygen
real time in-vivo dosimetry for gynecologic brachytherapy

Conditions: Cancer of the Cervix, Cancer of the Endometrium

Summary: this is an observational study. the purpose is to determine the feasibility of using a novel nano-scintillator fiber-optic dosimeter (nanofod) for the real time dosimetric monitoring of brachytherapy treatment. women with gynecologic cancers treated with brachytherapy as part of their standard therapeutic regimen will represent the study population.

brachytherapy is a curative treatment for many malignancies, brachytherapy delivers a high radiation dose to a very small and well-specified target within a patient with cancer. yet there is no current convenient, inexpensive, real time method of confirming the radiation dose delivered. there is no current monitoring or fail-safe device for radiation oncologists and their patients if the radiation dose becomes too high, especially to radiation sensitive organs, or conversely if the target receives too little dose.high dose-rate(hdr) brachytherapy is a highly advanced radiation-based cancer treatment, where a very small radioactive source, iridium-192, is placed in or near the tumor through a catheter or channel. this provides a high radiation dose to the tumor in 5-15 minutes with a precise location, while minimizing radiation exposure to surrounding tissue and organs. this protocol will determine the feasibility of using a novel nano-material based fiber-optic dosimeter (nanofod) device, with dimensions less than 1 mm wide, to measure real-time, pin-point, in-vivo radiation dose given during radiation therapy treatments. the size of the device allows placement through a catheter or channel near areas of interest, or within already placed brachytherapy delivery catheters.

Eligibility criteria:
inclusion criteria: * histologically documented neoplasm of the female genital tract. * planned brachytherapy as part of standard of care treatment. * age \> 18 years * able to provide and execute informed consent exclusion criteria: * any clinical scenario in which the nanofod placement or reading would compromise the treatment efficacy, or endanger the patient in any way.
pediatric head lice study product comparison

Conditions: Head Lice

Summary: * to evaluate the efficacy of licemd for the treatment of head lice in a pediatric population. * to evaluate the safety of licemd in a pediatric population.

head lice, or pediculus humanus capitis, cause an estimated 6 to 12 million infestations per year in the u.s., most commonly affecting children 3 to 11 years of age. despite common perceptions, head lice crawl, and cannot hop or fly. for this reason, transmission occurs most often by human head-to-head contact, and much less commonly by the sharing of personal items such as hats, coats, combs, or towels. because head lice feed on human blood, they cannot live on pets and are only viable 1-2 days on surfaces other than the human head.

Eligibility criteria:
inclusion criteria: * subject inclusion criteria * current lice infestation, confirmed by school nurse. must have live lice - not just eggs. a minimum of one live louse and 10 viable eggs must be seen or three live lice. * male or female child; age 3 - 12 * willing to participate in study, and parent/guardian sign informed consent * parent/guardian must be able to read and follow directions and complete all questionnaires * for children/parents who agree to the experimental arm of the study, agree not to use any other head lice product or home remedy lice treatment during the study. exclusion criteria: * no live lice, only eggs. * less than three live lice observed with less than ten viable eggs * no hair on the head * buzz cut or crew cut * use of other lice treatment or home remedy lice treatment within the past 4 weeks * chronic scalp disorder (such as psoriasis) that would limit the school nurse's ability to detect lice and/or identify adverse events * currently taking an antibiotic * does not follow instructions.

Keywords: lice
cardiac amyloidosis screening at trigger finger release

Conditions: Amyloidosis; Trigger Finger; Transthyretin Amyloidosis; Primary Amyloidosis of Light Chain Type

Summary: the investigators will prospectively evaluate for the presence of amyloid deposits in soft tissue samples obtained from patients undergoing trigger finger release surgery. patients who have tissue that stains positive for amyloid will be referred to an amyloidosis specialist.

a prospective study in 2001 showed that 23% (n = 47) of biopsies for idiopathic trigger finger were positive for congo red staining but negative for attr and al amyloid via immunohistochemistry. however, mass spectrometry is now the preferred method to type amyloid tissue. trigger finger pathology involves the same flexor tenosynovium that passes through the carpal tunnel and has been biopsied to diagnose amyloidosis. our recent study found that 10% of older patients undergoing carpal tunnel release surgery were positive for amyloidosis, with 20% of that group presenting with cardiac involvement. 60% of the amyloid-positive group had a history of trigger finger. surgical intervention for trigger finger could provide an opportunity to screen for amyloidosis through tenosynovial biopsy. this study will look at the prevalence of amyloidosis in patients undergoing surgical intervention for idiopathic trigger finger. the study hypothesis is at least 10% of such patients will be positive for amyloidosis.

Eligibility criteria:
inclusion criteria: * age ≥50 years at the time of surgical biopsy. * undergoing surgical intervention for idiopathic trigger finger. * able to consent. exclusion criteria: * known history of amyloidosis.

Keywords: surgery surgical release biopsy
evaluate the safety and efficacy of tafasitamab and lenalidomide in combination with gemcitabine and oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large b-cell lymphoma

Conditions: DLBCL

Summary: this is a randomized, multi-center, phase 3 study of tafasitamab and lenalidomide in combination with gemcitabine and oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large b-cell lymphom


Eligibility criteria:
inclusion criteria: 1. 18 years and older. 2. one of the histologies of dlbcl confirmed by participated sites below with，not otherwise specified;t-cell/histiocyte-rich large b-cell lymphoma;epstein-barr virus (ebv) positive dlbcl (ebv-positive dlbcl); composite lymphoma with a dlbcl component with a subsequent dlbcl relapse; disease transformed from an earlier diagnosis of low-grade lymphoma into dlbcl with dlbcl treatment failure. 3. availability of tumor tissue biopsied post last line of therapy and prior to current study treatment for the patients enrolled in safety and tolerability stage. 4. relapsed/refractory (r/r) dlbcl, at least one (≥1) but no more than three (≤3) line of prior systemic therapies. 5. patients who have not received high dose therapy/stem cell transplantation (hdt/sct) must be ineligible for hdt/sct. 6. at least one measurable site of disease per ct or magnetic resonance imaging (the longest axis of the lymph node lesion is \> 1.5 cm, and the longest diameter of the extra-nodal lesion is \> 1.0 cm). 7. ecog ps score of 0 to 2. 8. subject must have adequate organ functions, and the laboratory values comply with the protocol requirements. 9. life expectancy of ≥ 3 months. 10. informed consent before screening and can understand and comply with the requirements of the study. exclusion criteria: 1. existing or prior history of other malignant tumor within 3 years, except for those who have received curative treatment. 2. current or history of central nervous system (cns) lymphoma. 3. known high-grade b-cell lymphoma with myc and bcl2 and/or bcl6 rearrangements. 4. primary mediastinal b-cell lymphoma. 5. history of allogeneic stem-cell transplantation. 6. prior exposure to anti-cd19 treatment, and (or) failed with gemcitabine plus platinum-based agent combination therapy. 7. current toxicity of ≥ grade 2 from prior anti-cancer therapy (except for alopecia, neutrophil, hemoglobin and platelets). 8. clinically significant cardiovascular disease or nervous system disease. 9. history of deep venous thrombosis/embolism, threatening thromboembolism or known thrombophilia or are at a high risk for a thromboembolic event in the opinion of the investigator and who are not willing/able to take venous thromboembolic event prophylaxis during the entire treatment period. 10. uncontrolled systemic infection requiring parenteral intravenous anti-infective therapy. 11. known human immunodeficiency virus (hiv), or serologic status reflecting active hepatitis b or c infection.
outreach for patients with uncompleted colorectal cancer screening orders

Conditions: Colorectal Cancer Screening; Prevention & Control

Summary: the purpose of this study is to evaluate whether patient outreach is effective at increasing compliance with preventive screenings ordered by their physician. we hypothesize that educational outreach may increase completion rates.

we designed an intervention to focus on patients who have received and accepted a referral for colonoscopy, yet have exhibited some barriers to screening as demonstrated by a lack of screening completion. we conducted a randomized controlled trial to assess the effects of a multicomponent intervention (patient reminder, print and multimedia materials) on colorectal screening completion among this target population.

Eligibility criteria:
inclusion criteria: * patient's physician has ordered a preventive screening test * patient has not completed this test in 3 months * patient of northwestern medical faculty foundation general internal medicine clinic. exclusion criteria: * patient has been given a more recent order for the same screening test. * patient has significant life stress as noted in the electronic health record (ehr)

Keywords: education preventive service screening
breathing rescue for sudep prevention

Conditions: Focal Epilepsy

Summary: the purpose of this study is to precisely delineate human brain networks that modulate respiration and identify specific brain areas and stimulation techniques that can be used to prevent seizure-induced breathing failure.


Eligibility criteria:
inclusion criteria: * diagnosis of intractable focal epilepsy * admitted to the epilepsy monitoring unit (emu) at memorial hermann-texas medical center for intracranial subdural strips, grids, or depth electrode placement study (invasive video-eeg) exclusion criteria: * respiratory, cardiac or cerebrovascular disease * pregnancy * prisoners
erythropoietin (epo) to protect renal function after cardiac surgery

Conditions: Kidney Failure; Renal Failure

Summary: the purpose of this study is to evaluate the potential of erythropoietin in reducing risk and degree of acute kidney injury after cardiac surgery.

acute kidney injury is a common complication after cardiac surgery and is associated with decreased long-term survival. several experimental and animal studies have showed cytoprotective, preconditioning and anti-apoptotic effects of high dose erythropoietin. clinical studies in human have also suggested that high dose erythropoietin has preconditioning effects against injury after ischemia and reperfusion on different organs in human, such as brain, heart, liver, and kidneys. administration of epo in high doses in conjunction with cardiac surgery has shown to be safe with no direct side-effects. the investigators therefore hypothesize that a preconditioning effect of erythropoietin before cardiac surgery can reduce the level of renal dysfunction after surgery in a group with preoperative renal impairment.

Eligibility criteria:
inclusion criteria: * the patient is scheduled for non-emergent cabg surgery. * cyc egfr or mdrd egfr \< 60 ml/min. * the patient has given his/her written consent to participate exclusion criteria: * the patient has an uncontrolled hypertension. * hypersensitivity to the active drug. * the patient is pregnant or is a fertile woman (\<50 years). * the patient has been treated with erythropoietin within 4 weeks prior to the surgery. * preoperative cyc egfr or mdrd egfr is \< 15, or the patient is treated with dialysis. * the patient has a known malignancy. * the patient is planned for off-pump cabg surgery. * the patient is included in other ongoing clinical trial. yes / no * clinically judgment by the investigator that the patient should not participate in the study.

Keywords: erythropoietin erythropoetin cardiac surgery ischemia reperfusion renal function cystatin c creatinine safety
family history study of alcohol consumption using memantine

Conditions: Alcohol Drinking

Summary: the purpose of this study is to evaluate the effects of the study medication, memantine (placebo, 20 mg or 40 mg/day) on alcohol drinking behavior in a laboratory setting in which participants are given an initial drink of alcohol followed by the choice to drink up to 12 more drinks over a three-hour period. we hypothesize that memantine will reduce craving and number of drinks consumed prior to and after exposure to the initial drink of alcohol and during the three hour drinking period. we will also evaluate the influence of family history of alcoholism on the efficacy of memantine in reducing alcohol drinking behavior.


Eligibility criteria:
inclusion criteria: * ages 21-50 * able to read english at 6th grade level or higher and to complete study evaluations * regular alcohol drinker exclusion criteria: * individuals who are seeking alcohol treatment * medical conditions that would contraindicate the use of memantine * regular use of other substances

Keywords: alcohol drinking memantine
motor imagery technique on lower limb function among stroke patients.

Conditions: Spasticity as Sequela of Stroke; Gait, Hemiplegic; Quality of Life

Summary: to determine the effects of motor imagery technique on lower limb function among stroke patient. to determine the effects of motor imagery technique on lower limb spasticity among stroke patients. to determine the effects of motor imagery technique on gait among stroke patients. to determine the effects of motor imagery technique on quality of life among stroke patients

stroke affected the functional capacities and the state of health thus altered quality of life.

Eligibility criteria:
inclusion criteria: * adult without adhd by adult adhd self-report scale score. * history of no more than one stroke. * lower limb muscles spasticity with the grade 1+ or 2 on modified ashworth in scale. * mini-mental status score more than 25. * patients who are less than 6 months post-stroke. * modified rankin scale score is 4. exclusion criteria: * lesion of frontal, parietal and basal ganglia * excessive spasticity that is score of\>3 on modified ashworth spasticity scale. * any musculoskeletal disorder impeding lower limb function. * participating in any experimental rehabilitation or drug studies. * bed ridden patient. * subjects psychiatric disorder or dementia. * any neglect of space on the affected side, or any other neurological disease or auditory or visual.

Keywords: gait lower limb function motor imagery